Jeff S. King, Ph.D., Chief Operating Officer
Dr. King was Senior Manager of Lead Validation at Rosetta Inpharmatics, (acquired by Merck in 2001). He directed a multi-talented team to build a production cell culture facility and develop methodologies for gene expression profiling of compounds in human cell lines. Prior to joining Rosetta, he was Manager of Compound Profiling at Acacia Biosciences, where he helped develop a full-genome expression-profiling platform in yeast. Dr. King received a B.S. degree in engineering physics from the University of Arizona and a Ph.D. degree in biophysics from the University of California, Berkeley. Previously he was an Assistant Research Molecular Biologist at the University of California, San Francisco and a Human Frontier Postdoctoral Fellow at the University of Bern in Switzerland. Dr. King has an issued patent on a device for high-throughput transformation of cells and is an inventor on several pending drug target patents.